I-SPY 2 breast cancer trial as a model for innovation in Alzheimer disease therapies

JAMA Neurology

Volumn 74, Issue 9, 2017, Pages 1027-1028

  Messmer, Mindi F ^a,b   Wilhelm, Erin E ^a,c   Shoulson, Ira ^a,c  

^a GEORGETOWN UNIVERSITY   (United States)

^b VistaNova Consulting   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; NERATINIB; PLACEBO; TRASTUZUMAB EMTANSINE; VELIPARIB; ANTINEOPLASTIC AGENT;

ALZHEIMER DISEASE; BAYES THEOREM; BREAST CANCER; BREAST SURGERY; CLINICAL TRIAL (TOPIC); HUMAN; INTERSECTORAL COLLABORATION; INVESTMENT; PRIORITY JOURNAL; SHORT SURVEY; STUDY DESIGN; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; EXPERIMENTAL THERAPY; FEMALE; MOLECULAR IMAGING; PROCEDURES;

ALZHEIMER DISEASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MOLECULAR IMAGING; THERAPIES, INVESTIGATIONAL;

EID: 85029581377     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.1528     Document Type: Short Survey

References (8)

1. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline. Alzheimers Res Ther. 2014;6(4):37.
2. US Food and Drug Administration. The voice of the patient: Huntington’s disease. https://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM491603.pdf. Updated May 2016. Accessed May 2016.
3. US Food and Drug Administration. Guidance for industry, Alzheimer’s disease: developing drugs for the treatment of early stage disease. Draft guidance. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338287.pdf. Accessed February 2013.
4. Strobel G. NIH Director announces $100M prevention trial of Genentech antibody. Alzheimer's Research Forum. http://alzforum.org/new/detail.asp?id=3155. Updated May 21, 2012. Accessed June 19, 2017.
5. Simon R. Genomic alteration-driven clinical trial designs in oncology. Ann Intern Med. 2016;165(4): 270-278.
6. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2. Clin Pharmacol Ther. 2009;86(1):97-100.
7. Aguirre E, Kang S, Hoare Z, Edwards RT, Orrell M. How does the EQ-5D perform when measuring quality of life in dementia against two other dementia-specific outcome measures? Qual Life Res. 2016;25(1):45-49.
8. Alzheimer’s Association. Changing the trajectory of Alzheimer’s disease: how a treatment by 2025 saves lives and dollars. https://www.alz.org/documents_custom/trajectory.pdf. Published 2015. Accessed 2015.